Neoprobe, a developer of oncology surgical and diagnostic products, has submitted a new drug application for Lymphoseek (tilmanocept) to the FDA.

Watson Laboratories, a subsidiary of Watson Pharmaceuticals, has received tentative approval from the FDA for its rosuvastatin zinc 5, 10, 20 and 40 mg tablets. Watson's rosuvastatin zinc tablets are a salt form of AstraZeneca's Crestor (rosuvastatin calcium) tablets.

Immunogene therapy is safe for treating glioblastomas, even when combined with radiation therapy, according to a report published online Aug. 15 in Journal of Clinical Oncology. The findings suggested that the therapy might also stimulate an immune response against the tumor.

The electronic tattoo that topped mainstream-media news sites Fridayby noon it had sparked more than 500 headline links on Google Newsholds real promise for healthcare applications. In a paper published in the Aug. 12 edition of the journal Science, researchers tell how they designed the ultra-thin, skin-like electronic patch with components for sensing, medical diagnostics, communications and human-machine interfaces.

Agfa Healthcare is now selling its mobile direct radiography (DR) DX-D system in the U.S. and Canada. The DX-D 100 is designed for the mobile environments, including intensive care units (ICUs), emergency departments, operating rooms or at the bedside.

Canon U.S.A. will preview its CXDI-80C Wireless Digital Radiography (DR) system, along with its CXDI-501 DR systems, at the 2011 American Healthcare Radiology Administrators (AHRA) Exposition, Aug. 14-17, in Dallas.

The Government Accountability Office (GAO) has found that, of the $516 billion in Medicare paid to physicians, hospitals and other healthcare providers in 2010, some $48 billion was for improper claims. The same report showed that Medicare accounted for 38 percent of all improper payments found in the federal government last year.

While evidence-based guidelines seek to portray the ins and outs of when and when not to perform a procedure, there are still gray areas in terms of how to treat certain patients whose indications may fall outside the guidelines. To add to these types of gray areas, hospitals also vary on cost-saving and diagnoses strategies. What could these types of variations mean for the future of clinical practice?